Publisher
Springer Science and Business Media LLC
Reference6 articles.
1. Alexander GC, Emerson S, Kesselheim AS. Evaluation of aducanumab for Alzheimer’s disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA. 2021;325(17):1717-8.
2. Daval CJR, Teng TW, Russo M, Kesselheim AS. Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021. JAMA Health Forum. 2023;4(7):e231718. https://doi.org/10.1001/jamahealthforum.2023.1718.
3. Daval CJR, Sarpatwari A, Kesselheim AS. Unwanted advice? Frequency, characteristics, and outcomes of negative advisory committee votes for FDA-approved drugs. Health Aff. 2022;41(5):713–21.
4. Joseph A. Q&A: Califf on obesity drugs, advisory panels, and how threats hurt recruitment at FDA. STAT News. Published March 7, 2023. https://www.statnews.com/2023/03/07/fda-califf-weight-loss-drugs-recruitment/. Accessed 30 Sept 2023.
5. European Medicines Agency. EMA guide to information on human medicines evaluated by EMA. Published May 6, 2020. https://www.ema.europa.eu/en/documents/other/guide-information-human-medicines-evaluated-european-medicines-agency-what-agency-publishes-when_en.pdf. Accessed 30 Sept 2023.